Clinical trial
A Phase IIb Randomized Double-Blinded Positive Controlled Trial to Evaluate the Immunogenicity and Safety Study of the 3rd Booster Dose Using the High or Medium Dose of Inactivated (CoronaVac®) Vaccine in Healthy Adults Who Have Completed Two Doses of CoronaVac® or the mRNA Vaccine (Comirnaty) in Turkey
NCT05150496 is registered in ClinicalTrials.gov with Sinovac Research and Development Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase IIb Randomized Double-Blinded Positive Controlled Trial to Evaluate the Immunogenicity and Safety Study of the 3rd Booster Dose Using the High or Medium Dose of Inactivated (CoronaVac®) Vaccine in Healthy Adults Who Have Completed Two Doses of CoronaVac® or the mRNA Vaccine (Comirnaty) in Turkey
- Lead sponsor
- Sinovac Research and Development Co., Ltd.
- Phase
- Phase 2
- Overall status
- Suspended
- Start date
- December 15, 2022
- Completion date
- January 15, 2023
- Enrollment
- 640 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.